Erasca (ERAS) Competitors $1.42 -0.05 (-3.08%) Closing price 03:59 PM EasternExtended Trading$1.42 +0.00 (+0.35%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ERAS vs. VERA, IOVA, PRAX, GLPG, WVE, APGE, EVO, IRON, ARQT, and AMPHShould you be buying Erasca stock or one of its competitors? The main competitors of Erasca include Vera Therapeutics (VERA), Iovance Biotherapeutics (IOVA), Praxis Precision Medicines (PRAX), Galapagos (GLPG), Wave Life Sciences (WVE), Apogee Therapeutics (APGE), Evotec (EVO), Disc Medicine (IRON), Arcutis Biotherapeutics (ARQT), and Amphastar Pharmaceuticals (AMPH). These companies are all part of the "pharmaceutical products" industry. Erasca vs. Vera Therapeutics Iovance Biotherapeutics Praxis Precision Medicines Galapagos Wave Life Sciences Apogee Therapeutics Evotec Disc Medicine Arcutis Biotherapeutics Amphastar Pharmaceuticals Vera Therapeutics (NASDAQ:VERA) and Erasca (NASDAQ:ERAS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership, community ranking and analyst recommendations. Do analysts prefer VERA or ERAS? Vera Therapeutics presently has a consensus price target of $65.44, indicating a potential upside of 128.99%. Erasca has a consensus price target of $5.70, indicating a potential upside of 302.83%. Given Erasca's higher possible upside, analysts clearly believe Erasca is more favorable than Vera Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vera Therapeutics 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 3 Strong Buy rating(s) 3.20Erasca 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer VERA or ERAS? In the previous week, Vera Therapeutics had 6 more articles in the media than Erasca. MarketBeat recorded 6 mentions for Vera Therapeutics and 0 mentions for Erasca. Vera Therapeutics' average media sentiment score of 0.16 beat Erasca's score of 0.00 indicating that Vera Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Vera Therapeutics Neutral Erasca Neutral Does the MarketBeat Community believe in VERA or ERAS? Vera Therapeutics received 14 more outperform votes than Erasca when rated by MarketBeat users. However, 71.43% of users gave Erasca an outperform vote while only 65.00% of users gave Vera Therapeutics an outperform vote. CompanyUnderperformOutperformVera TherapeuticsOutperform Votes3965.00% Underperform Votes2135.00% ErascaOutperform Votes2571.43% Underperform Votes1028.57% Is VERA or ERAS more profitable? Erasca's return on equity of -42.26% beat Vera Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Vera TherapeuticsN/A -50.13% -39.50% Erasca N/A -42.26%-34.97% Do insiders & institutionals have more ownership in VERA or ERAS? 99.2% of Vera Therapeutics shares are owned by institutional investors. Comparatively, 67.8% of Erasca shares are owned by institutional investors. 21.7% of Vera Therapeutics shares are owned by insiders. Comparatively, 21.5% of Erasca shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has preferable earnings and valuation, VERA or ERAS? Vera Therapeutics is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVera TherapeuticsN/AN/A-$95.99M-$2.61-10.95ErascaN/AN/A-$125.04M-$0.83-1.70 Which has more volatility & risk, VERA or ERAS? Vera Therapeutics has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500. Comparatively, Erasca has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500. SummaryVera Therapeutics beats Erasca on 9 of the 16 factors compared between the two stocks. Get Erasca News Delivered to You Automatically Sign up to receive the latest news and ratings for ERAS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ERAS vs. The Competition Export to ExcelMetricErascaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$400.06M$7.04B$5.78B$8.98BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-1.706.1326.4618.82Price / SalesN/A313.78457.6880.73Price / CashN/A67.8344.0437.47Price / Book0.676.747.634.64Net Income-$125.04M$138.11M$3.18B$245.69M7 Day Performance-9.87%-2.02%-1.82%-2.63%1 Month Performance-25.53%-1.54%0.22%-2.37%1 Year Performance-26.30%-3.14%17.49%13.65% Erasca Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ERASErasca2.1471 of 5 stars$1.42-3.1%$5.70+302.8%-25.9%$400.06MN/A-1.70120Gap UpVERAVera Therapeutics2.4205 of 5 stars$27.46-19.7%$65.44+138.3%-33.7%$1.74BN/A-10.5240High Trading VolumeIOVAIovance Biotherapeutics4.0441 of 5 stars$5.57+4.3%$22.69+307.3%-53.4%$1.70B$1.19M-3.74500PRAXPraxis Precision Medicines1.9418 of 5 stars$90.77+4.7%$145.20+60.0%+97.9%$1.69B$2.45M-8.81110GLPGGalapagos0.2277 of 5 stars$25.44-0.2%$26.75+5.1%-32.2%$1.68B$259.40M0.001,123WVEWave Life Sciences4.3628 of 5 stars$10.81+0.1%$22.22+105.6%+175.7%$1.65B$113.31M-9.74240Positive NewsGap UpAPGEApogee Therapeutics2.2452 of 5 stars$36.54+0.8%$89.71+145.5%-1.6%$1.65BN/A-15.1091EVOEvotec1.7977 of 5 stars$4.58-0.2%$5.93+29.5%-39.6%$1.62B$845.74M0.005,061IRONDisc Medicine1.5632 of 5 stars$54.10flat$88.90+64.3%-18.2%$1.61BN/A-13.5930Insider TradeNews CoverageARQTArcutis Biotherapeutics2.2974 of 5 stars$12.78+3.8%$16.60+29.9%+41.6%$1.50B$59.61M-7.14150Upcoming EarningsAMPHAmphastar Pharmaceuticals4.427 of 5 stars$31.02-2.3%$50.33+62.3%-40.3%$1.49B$644.40M10.341,761 Related Companies and Tools Related Companies Vera Therapeutics Alternatives Iovance Biotherapeutics Alternatives Praxis Precision Medicines Alternatives Galapagos Alternatives Wave Life Sciences Alternatives Apogee Therapeutics Alternatives Evotec Alternatives Disc Medicine Alternatives Arcutis Biotherapeutics Alternatives Amphastar Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ERAS) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Erasca, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Erasca With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
